Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
March 2012, Vol 3, No 2
March 2012, Vol 3, No 2
Wilshire Oncology Medical Home Pilot: Reengineering Cancer Care
Best Practices
,
Policies & Guidelines
March 2012, Vol 3, No 2
Interview with Linda Bosserman, MD, Clinical Oncologist and President of Wilshire Oncology Medical Group, La Verne, CA
Read Article
Everolimus Has Minimal Economic Impact on Treatment of Pancreatic NETs
By
Caroline Helwick
Gasterol Intestinal Symposium
March 2012, Vol 3, No 2
San Francisco, CA—Using a prediction model to analyze the impact of adding targeted agents to the treatment of pancreatic neuroendocrine tumors (pNETs), everolimus (Afinitor) had a minimal overall impact on healthcare expenditures, by reducing infusions and surgical procedures costs, according to a study presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article
AMA Delegates and Oncologists Balk at ICD-10 Implementation
By
Caroline Helwick
Health Policy
,
Policies & Guidelines
March 2012, Vol 3, No 2
New Orleans, LA—According to the American Medical Association (AMA) and many oncologists, the
International Classification of Diseases, Tenth Revision (ICD-10)
diagnostic coding system will be a needless and expensive burden to oncology practices, without enhancing patient care.
Read Article
External Beam Radiation More Toxic, Costlier than Brachytherapy or Prostatectomy
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—In a retrospective long-term comparative analysis of 3 prostate cancer treatment strategies, treatment with external beam radiation therapy (EBRT) was more toxic and costlier than prostatectomy and brachytherapy, according to Cleveland Clinic researchers who presented their data at the 2012 annual Genitourinary Cancers Symposium.
Read Article
FDA Updates Imatinib's Label to 36 Months of Use after Removal of GIST
FDA Approvals, News & Updates
March 2012, Vol 3, No 2
The US Food and Drug Administration (FDA) approved an updated label for imatinib (Gleevec; Novartis) for the use of the drug in adults after the surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).
Read Article
House Introduces Bill to Expedite FDA Drug Review
FDA Approvals, News & Updates
March 2012, Vol 3, No 2
A new House bill—the Drug Shortage Prevention Act (H.R. 3839)— received bipartisan support to expedite the FDA review of drugs in shortage, improve communication within the agency and with stakeholders about possible shortages, and increase Drug Enforcement Administration (DEA) quotas for medications in short supply.
Read Article
BRAF Inhibitors Linked to squamous-Cell Carcinoma in Patients with RAS Mutations
In the Literature
March 2012, Vol 3, No 2
As many as 15% to 30% of patients who receive BRAF inhibitors (eg, vemurafenib, dabrafenib) for the treatment of metastatic melanoma develop nonmelanoma skin cancers. Data from a new study suggest that this paradoxical effect may be caused by squamous-cell carcinoma cell lines with
RAS
mutation that proliferate on exposure to these drugs (Su F, et al.
N Engl J Med
. 2012;366:207-215).
Read Article
Statins Have Protective Effects Against Hepatocellular Cancer in HBV Infection
In the Literature
March 2012, Vol 3, No 2
Several studies have suggested that statins may have protective effects against cancer. The results of the first study to investigate the association between statin therapy in patients with chronic hepatitis B virus (HBV) infection and the risk for hepatocellular carcinoma (HCC) were recently published (Tsan YT, et al.
J Clin Oncol
. 2012;30:623-630).
Read Article
Family History of Gastric Cancer Associated with Improved Survival in Patients with Advanced Cancer
In the Literature
March 2012, Vol 3, No 2
A new study has now investigated the prognosis of patients with gastric cancer who have a family history of the disease and have undergone gastrectomy (Han MA, et al.
J Clin Oncol.
2012;30:701-708).
Read Article
Ruxolitinib Boosts Quality-of-Life Outcomes in Myelofibrosis
In the Literature
March 2012, Vol 3, No 2
The treatment options for myelofibrosis are very limited, with ruxolitinib the potent Janus kinase (JAK) 1 and 2 inhibitor, being the first and only drug approved specifically for this condition late last year.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma